Holen Sie sich die Stockscreener-App
10.14
0.98%
-0.10
Schlusskurs vom Vortag:
$10.24
Offen:
$10.23
24-Stunden-Volumen:
1.09M
Relative Volume:
0.56
Marktkapitalisierung:
$1.19B
Einnahmen:
$59.61M
Nettoeinkommen (Verlust:
$-262.14M
KGV:
-1.8303
EPS:
-5.54
Netto-Cashflow:
$-247.49M
1W Leistung:
+9.50%
1M Leistung:
+21.58%
6M Leistung:
+2.22%
1J Leistung:
+439.36%
1-Tages-Spanne:
$10.05
$10.37
1-Wochen-Bereich:
$8.90
$10.72
52-Wochen-Spanne:
$1.76
$13.17
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Firmenname
Arcutis Biotherapeutics Inc
Sektor
Branche
Telefon
805-418-5006
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Vergleichen Sie ARQT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ARQT | 10.14 | 1.19B | 59.61M | -262.14M | -247.49M | -5.54 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-10-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-09-07 | Eingeleitet | Needham | Buy |
| 2022-03-17 | Eingeleitet | Goldman | Buy |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Hochstufung | Goldman | Neutral → Buy |
| 2020-10-08 | Eingeleitet | Truist | Buy |
| 2020-02-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Eingeleitet | Cowen | Outperform |
| 2020-02-25 | Eingeleitet | Goldman | Neutral |
| 2020-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Position Increased by Jennison Associates LLC - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average - MSN
Arcutis Biotherapeutics SVP sells $17,190 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics SVP sells $17,190 in stock - Investing.com India
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now - Yahoo Finance
Arcutis Biotherapeutics SVP sells shares worth $712,620 - Investing.com
Arcutis Biotherapeutics SVP sells shares worth $712,620 By Investing.com - Investing.com UK
Arcutis Biotherapeutics: What Lies Ahead (NASDAQ:ARQT) - Seeking Alpha
Long Term Trading Analysis for (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up? - Seeking Alpha
Arcutis Biotherapeutics director sells $94,238 in stock By Investing.com - Investing.com Australia
Insider Selling: Director Terrie Curran Sells Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus.com
Arcutis Biotherapeutics director sells $94,238 in stock - Investing.com
Rubric Capital Management LP's Strategic Acquisition in Arcutis Biotherapeutics Inc - GuruFocus.com
Arcutis' ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour - The Manila Times
Arcutis' ZORYVE Wins Glamour's Best Eczema Treatment Award, Targets 26M Patient Market | ARQT Stock News - StockTitan
GSA Capital Partners LLP Has $2.21 Million Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Chronic Hand Eczema Pipeline Update 2024: FDA Approvals, - openPR
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call Transcript - Insider Monkey
Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Arcutis Biotherapeutics reports robust growth for ZORYVE - Investing.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlig - GuruFocus.com
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... - Yahoo Finance
Arcutis Biotherapeutics Reports Strong Q3 2024 Results - TipRanks
Morgan Stanley's Strategic Reduction in Arcutis Biotherapeutics Holdings - GuruFocus.com
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings: Revenue Sur - GuruFocus.com
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcutis Q3 Revenue Soars 452% to $44.8M, ZORYVE Sales Surge Amid FDA Progress | ARQT Stock News - StockTitan
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Arcutis Biotherapeutics exec sells $43,551 in stock - Investing.com India
Trend Tracker for (ARQT) - Stock Traders Daily
Arcutis biotherapeutics CMO sells $134,092 in stock - Investing.com India
Arcutis Biotherapeutics director sells $86,541 in stock - Investing.com
Arcutis biotherapeutics CMO sells $134,092 in stock By Investing.com - Investing.com UK
Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result - GuruFocus.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
abrdn plc Buys 333,200 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 8.7% HigherHere's Why - MarketBeat
AMI Asset Management Corp Buys 59,487 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - MSN
Jefferies Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy Recommendation - MSN
Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):